000			03175nam a22004815i 4500
001			978-88-470-2613-1
003			DE-He213
005			20140220083336.0
007			cr nn 008mamaa
008			120714s2012 it | s |||| 0|eng d
020			_a9788847026131 _9978-88-470-2613-1
024	7		_a10.1007/978-88-470-2613-1 _2doi
050		4	_aR895-920
072		7	_aMMPH _2bicssc
072		7	_aMMP _2bicssc
072		7	_aMED008000 _2bisacsh
082	0	4	_a616.0757 _223
100	1		_aAglietta, Massimo. _eeditor.
245	1	0	_aImaging Tumor Response to Therapy _h[electronic resource] / _cedited by Massimo Aglietta, Daniele Regge.
264		1	_aMilano : _bSpringer Milan : _bImprint: Springer, _c2012.
300			_aXVII, 157 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aPart I Methodological Bases -- 1 Surrogate Endpoints of Clinical Benefit -- 2 Response to Treatment: the Role of Imaging -- Part II RECIST and Beyond: Assessing the Response to Treatment in Metastatic Disease -- 3 Gastrointestinal Stromal Tumors -- 4 Renal Cancer -- 5 Liver Metastases in Colon Cancer -- Part III RECIST and Beyond: Assessing the Response to Treatment in Locally Advanced Disease -- 6 Neoadjuvant Therapy in Breast Cancer -- 7 Lung Cancer -- 8 Pancreatic Cancer -- 9 Hepatocellular Carcinoma.
520			_aMeasurement of solid tumor response to treatment relies mainly on imaging. WHO tumor response criteria and, more recently, RECIST (response evaluation criteria in solid tumors) have provided means to objectively measure tumor response in clinical trials with imaging. These guidelines have been rapidly adopted in clinical practice to monitor patient treatment and for therapy planning. However, relying only on anatomical information is not always sufficient when evaluating new drugs that will reduce a tumor's functionality while preserving its size. Finding more reliable and reproducible measures of tumor response is one of the most important and difficult challenges facing modern radiology as it requires an entirely new approach to imaging. The aim of this book is to address the assessment of response to treatment by adopting a multidisciplinary perspective, just as occurs in real life in a comprehensive cancer center. Oncologists and imaging experts consider two cancer models, locally advanced disease and metastatic disease, jointly exploring both conventional and advanced means of measuring response to standard treatment protocols and new targeted therapies.
650		0	_aMedicine.
650		0	_aRadiology, Medical.
650		0	_aNuclear medicine.
650		0	_aOncology.
650	1	4	_aMedicine & Public Health.
650	2	4	_aImaging / Radiology.
650	2	4	_aOncology.
650	2	4	_aNuclear Medicine.
700	1		_aRegge, Daniele. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9788847026124
856	4	0	_uhttp://dx.doi.org/10.1007/978-88-470-2613-1
912			_aZDB-2-SME
999			_c104179 _d104179